Insulin resistance and vessel endothelial function

Journal of the Royal Society of Medicine, Supplement

Volumn 95, Issue 42, 2002, Pages 54-61

  Van Oostrom, A J H H M ^a   Castro Cabezas, M ^a   Rabelink, T J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; FATTY ACID; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CONFERENCE PAPER; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; THROMBOSIS; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPERLIPIDEMIAS; INSULIN RESISTANCE; RISK FACTORS;

EID: 0036341922     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (128)

1. Shattuck lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
2. Hyperinsulinemia as an independent risk factor for ischemic heart disease
3. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study
4. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15-year follow-up
5. Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome
6. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease
7. Insulin and atheroma, 20-yr perspective
8. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
9. Body-mass index and mortality in a prospective cohort of U.S. adults
10. Banting lecture 1988. Role of insulin resistance in human disease
11. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study
12. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
13. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is . . . or is it?
14. Intensive blood-glucose control with sulpbonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
15. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
16. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial
17. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study
18. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes
19. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus
20. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway
21. Atherogenesis: A postprandial phenomenon
22. Postprandial lipoproteins in non-insulin-dependent diabetes mellitus
23. Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease
24. Hypertriglyceridemia and its metabolic consequences as a risk factor for atheroseterotic cardiovascular disease in non-insulin-dependent diabetes mellitus
25. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities
26. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level
27. The postprandial state and risk of cardiovascular disease
28. Nitric oxide: Nature's naturally occurring leukocyte inhibitor
29. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors
30. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells
31. cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells
32. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction
33. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo
34. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide
35. Effect of insulin on human aortic endothelial nitric oxide synthase
36. Acute hyperglycemia induces an oxidative stress in healthy subjects
37. Non-invasive assessment of vascular function: Paradoxical vascular response to intravenous glucose in coronary heart disease
38. Syndrome X: Medical nutrition therapy
39. Mechanisms of angiogenesis and arteriogenesis
40. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogensis via nitric oxide
41. Nitric oxide and angiogenesis
42. Soluble L-selectin level is a marker for coronary artery disease in type 2 diabetic patients
43. Novel clinical markers of vascular wall inflammation
44. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: The Rotterdam study
45. Cell adhesion molecules in coronary artery disease
46. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients
47. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis
48. Endothelial function and coronary artery disease
49. Close relation of endothelial function in the human coronary and peripheral circulations
50. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function
51. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
52. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
53. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options
54. Endothelium-dependent vasodilation is related to the fatty acid composition of serum lipids in healthy subjects
55. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus
56. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation
57. Coronary angiography and intravascular ultrasound
58. Reproducibility of measurements of intima-media thickness and distensibility in the common carotid artery
59. Reproducibility of in vivo carotid intima-media thickness measurements: A review
60. Variability of flow mediated dilation: Consequences for clinical application
61. Association between wall shear stress and flow-mediated vasodilation in healthy men
62. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis
63. Functional improvement precedes structural regression of atherosclerosis
64. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus
65. Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes
66. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans
67. Lipoprotein lipase in diabetes
68. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides
69. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men
70. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes
71. Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects
72. Effect of statin versus fibrate on postprandial endothelial dysfunction: Role of remnant-like particles
73. Impaired flow-mediated vasoactivity during post-prandial phase in young healthy men
74. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes
75. Postprandial triglycerides and endothelial function
76. Dietary modulation of endothelial function: Implications for cardiovascular disease
77. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress
78. Lipids and the endothelium
79. What is oxidative stress?
80. Chylomicrons induce E-selectin and VCAM-1 expression in endothelial cells
81. Mechanism of free fatty acid-induced insulin resistance in humans
82. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus
83. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation
84. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: The RIAD study. Rick factors in impaired glucose tolerance for atherosclerosis and diabetes
85. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: An effect prevented by vitamins C and E
86. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells
87. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism
88. Hyperglycemia-induced ascorbic acid deficiency promotes endothelial dysfunction and the development of atherosclerosis
89. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
90. Nitric oxide availability in diabetes mellitus
91. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: Role of nitric oxide synthase?
92. Cardiovascular risk factors in type 2 diabetes: The role of hyperglycaemia
93. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation
94. Impaired postprandial tissue regulation of blood flow in insulin resistance: A determinant of cardiovascular risk?
95. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production
96. Hyperinsulinemia and vascular dysfunction: The role of nuclear factor-kappaB, yet again
97. Plasma endothelin-1 and total insulin exposure in diabetes mellitus
98. Weight loss and progression of early atherosclerosis in the carotid artery: A four-year controlled study of obese subjects
99. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal
100. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients
101. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM
102. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes
103. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes
104. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors
105. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease
106. Triglycerides and endothelial function in type 2 diabetes
107. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
108. The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimal-medial thickness: A pilot study
109. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
110. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors
111. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhihitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
112. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism
113. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress
114. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin
115. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
116. Vascular effects of ACE inhibition independent of the renin-angiotensin system in hypertensive renovascular disease: A randomized, double-blind, crossover trial
117. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function
118. Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: Effects of ACE inhibitors and fibrates
119. Troglitazone improves endothelial dysfunction in patients with insulin resistance
120. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans
121. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia
122. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial
123. Folate improves endothelial function in coronary artery disease: An effect mediated by reduction of intracellular superoxide?
124. Influence of folic acid on postprandial endothelial dysfunction
125. VEGF gene therapy: Stimulating angiogenesis or angioma-genesis?
126. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis
127. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF
128. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice